Back

Low cardiovascular event rates in patients treated with CAR T-cells: real-world outcomes from two independent cohorts

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Special populations in cardio-oncology Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jakob Christoph Voran

University Medical Center of Schleswig-Holstein, Kiel (Germany)

8 More presentations in this session

Presentation thumbnail
Dysfunctional high-density lipoproteins in breast cancer patients and tumor-bearing mice treated with chemotherapy
Professor S. Lecour (Cape Town, ZA)
Abstract Slides Video
Presentation thumbnail
Valvular heart disease in Cancer patiEntS - prevAlence, Relevance, and therapeutic management - preliminary results from the CESAR study
Doctor L. Hauptmann (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Novel biomarker-based machine learning model in personalized cardiotoxicity prediction.
Ms I. Liu (Austin, US)
Abstract Slides Video
Presentation thumbnail
The incidence and risk factors for early onset atrial fibrillation in allogeneic and autologous hematopoietic stem cell transplant patients
Ms L. Cai (Duarte, US)
Abstract Slides Video
Presentation thumbnail
Clinical and echocardiographic characteristics of neuroendocrine tumours and carcinoid heart disease: insights from a contemporary canadian cohort study
Mr J. Yoon (Vancouver, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Special populations in cardio-oncology

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular implications of CAR-T cell therapy: insights from a regional cardio-oncology program
thumbnail
Congress Presentation
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
thumbnail
Congress Presentation
Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources